Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Core Insights - Nuvectis Pharma, Inc. has provided updates on the Phase 1a dose-escalation study of NXP900, indicating robust pharmacodynamic responses and an acceptable safety profile with no dose limiting toxicity identified up to 250 mg/day [1][5][6] - The company is preparing to initiate the Phase 1b program, focusing on biomarker-selected cancers and evaluating NXP900 in combination with leading therapies for resistant non-small cell lung cancer (NSCLC) [4][5] Group 1: Clinical Study Highlights - NXP900 demonstrated systemic exposure that increased with dosage, achieving clinically relevant concentrations starting at 150 mg/day, with over 90% SRC inhibition observed in patient samples after a single dose [6] - The study included 29 patients with advanced cancers, with a median age of 62 years, where common treatment-emergent adverse events were mostly Grade 1-2 [6] Group 2: Preclinical Data and Rationale - Preclinical data supports NXP900's potential as a single agent and in combination with existing therapies to overcome resistance in NSCLC, particularly targeting YES1 gene amplifications and Hippo pathway alterations [1][3][4] - The addition of NXP900 to market-leading EGFR and ALK inhibitors reversed resistance, highlighting its potential in addressing unmet clinical needs in NSCLC [6] Group 3: Company Overview - Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for oncology, with NXP900 being an oral small molecule inhibitor of the SRC Family of Kinases [7] - The company is also developing another candidate, NXP800, for different cancer indications, showcasing a diverse pipeline in oncology [7]